{"a":[{"_":"Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets ","$":{"href":"/biotech/lupin-seeds-spinout-kaveri-cash-and-clinical-phase-cancer-assets","hreflang":"en"}}]}

Summary

Lupin has created Kaveri Therapeutics as a U.S. spinout with two clinical-phase cancer drug candidates and plans to raise capital for further development. Kaveri's programs address therapeutic areas pursued by major drugmakers including AstraZeneca, Bayer, and Bristol Myers Squibb.